Published in Int Urol Nephrol on April 28, 2017
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Vascular calcification: pathobiology of a multifaceted disease. Circulation (2008) 3.64
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab (2014) 1.57
The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One (2011) 1.40
Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol (2013) 1.10
Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int (2001) 1.09
Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab (2012) 1.04
Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int (2011) 1.00
Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant (2012) 0.99
Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab (2013) 0.97
Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab (2013) 0.93
Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int (2015) 0.89
Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract (2014) 0.89
Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant (2015) 0.87
Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease. Clin Exp Hypertens (2013) 0.86
Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int (2015) 0.86
Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant (2015) 0.81
Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia (2015) 0.81
Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. J Clin Endocrinol Metab (2015) 0.80
Sclerostin as a new key player in arteriovenous fistula calcification. Herz (2013) 0.79
Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol (2016) 0.78
High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients. Nephron (2016) 0.78
Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients. Clin Chim Acta (2015) 0.78